Clinical trials
NASH With Fibrosis clinical trials
Below are recruiting nash with fibrosis clinical trials, each written for real people, not researchers. We’re tracking 11 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06308757Recruiting
Studying a very low calorie keto diet for fatty liver disease with scarring
This trial tests whether a very low calorie ketogenic diet (a strict low-carb, high-fat diet) can help people with non-alcoholic steatohepatitis (NASH) who have liver scarring. Participants will follow this diet for a year and have two liver biopsies to see if their liver health improves.
BolognaAges 18 years+ - NCT06215716RecruitingPhase 3
Efruxifermin for NASH/MASH with liver scarring
This study tests a new medicine, efruxifermin, for people with NASH/MASH (fatty liver disease) and moderate liver scarring. It aims to see if the drug can help improve the liver's condition.
Birmingham, AlabamaAges 18–80 - NCT04442334Recruiting
European registry for people with fatty liver
This registry collects health and lifestyle information from adults with suspected or confirmed fatty liver (NAFLD) to help researchers better understand the condition. You may be asked about diet, exercise, alcohol intake, and some liver-related tests.
AntwerpAges 18–100 - NCT06707129Recruiting
New criteria to see if NASH liver scarring has reversed
This study is creating better ways to measure if liver scarring from NASH (a type of fatty liver disease) has improved. It may help doctors know if treatments are working.
Beijing, Beijing MunicipalityAges 18–70 - NCT06318169RecruitingPhase 3
Testing pegozafermin for MASH and liver fibrosis
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Birmingham, AlabamaAges 18–80 - NCT06138821Recruiting
Endoscopic sleeve gastroplasty for obesity and MASH
This study tests if a procedure called endoscopic sleeve gastroplasty helps people with obesity and a liver condition called MASH lose weight and improve their liver health. It might be an option if you have both obesity and MASH and haven't had weight-loss surgery before.
Boston, MassachusettsAges 18 years+ - NCT04366999Recruiting
Bariatric surgery for fatty liver disease in people with obesity
This trial looks at whether weight-loss (bariatric) surgery helps people with fatty liver disease, including “NASH,” and related liver scarring. If you have obesity and a confirmed liver fat diagnosis (and for NASH, biopsy-proven NASH with some fibrosis), the study may follow your outcomes after surgery.
Beijing, Beijing MunicipalityAges 16–65 - NCT07122700Recruiting
Better tests for fatty liver disease in people with metabolic issues
This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.
Miami, FloridaAges 18–75 - NCT03472157Recruiting
Bariatric surgery for severe NASH with advanced liver scarring
This study tests whether bariatric surgery (either sleeve gastrectomy or Roux-en-Y gastric bypass) improves severe nonalcoholic steatohepatitis (NASH) with advanced liver scarring in people who are obese. You may also need liver biopsies to confirm your liver disease before and after treatment.
LilleAges 18–65 - NCT03025074Recruiting
Blood sample bank for liver disease research
This study collects blood samples to build a “biobank” (a stored library of samples) for researchers studying liver diseases like hepatitis, fatty liver disease, and liver cancer. It may help future testing and treatments by allowing scientists to study patterns in people with and without liver conditions.
Buffalo, New YorkAges 7 years+ - NCT06588699RecruitingPhase 2
Digoxin for NASH liver disease study
This trial tests if the heart medication digoxin can help people with NASH (fatty liver disease with inflammation), who have moderate liver scarring. You will receive digoxin or a placebo for 24 weeks and have a liver biopsy before and after treatment to see if the medication reduces liver damage.
New Haven, ConnecticutAges 18–75
Hear when a new NASH With Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nash with fibrosis?
- Yes. Clin2 currently lists 11 recruiting nash with fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nash with fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nash with fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.